172 related articles for article (PubMed ID: 11551521)
1. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
2. Cannabimimetic properties of ajulemic acid.
Vann RE; Cook CD; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826
[TBL] [Abstract][Full Text] [Related]
3. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid.
Liu J; Li H; Burstein SH; Zurier RB; Chen JD
Mol Pharmacol; 2003 May; 63(5):983-92. PubMed ID: 12695526
[TBL] [Abstract][Full Text] [Related]
4. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.
Gonzalez EG; Selvi E; Balistreri E; Akhmetshina A; Palumbo K; Lorenzini S; Lazzerini PE; Montilli C; Capecchi PL; Lucattelli M; Baldi C; Gianchecchi E; Galeazzi M; Pasini FL; Distler JH
Ann Rheum Dis; 2012 Sep; 71(9):1545-51. PubMed ID: 22492781
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
Massi P; Vaccani A; Ceruti S; Colombo A; Abbracchio MP; Parolaro D
J Pharmacol Exp Ther; 2004 Mar; 308(3):838-45. PubMed ID: 14617682
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez C; de Ceballos ML; Gomez del Pulgar T; Rueda D; Corbacho C; Velasco G; Galve-Roperh I; Huffman JW; Ramón y Cajal S; Guzmán M
Cancer Res; 2001 Aug; 61(15):5784-9. PubMed ID: 11479216
[TBL] [Abstract][Full Text] [Related]
7. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells.
George KL; Saltman LH; Stein GS; Lian JB; Zurier RB
J Cell Physiol; 2008 Mar; 214(3):714-20. PubMed ID: 17786950
[TBL] [Abstract][Full Text] [Related]
8. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism.
Zygmunt PM; Andersson DA; Hogestatt ED
J Neurosci; 2002 Jun; 22(11):4720-7. PubMed ID: 12040079
[TBL] [Abstract][Full Text] [Related]
9. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma.
Ambrosio ALB; Dias SMG; Polikarpov I; Zurier RB; Burstein SH; Garratt RC
J Biol Chem; 2007 Jun; 282(25):18625-18633. PubMed ID: 17462987
[TBL] [Abstract][Full Text] [Related]
10. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.
Burstein S
AAPS J; 2005 Jun; 7(1):E143-8. PubMed ID: 16146336
[TBL] [Abstract][Full Text] [Related]
11. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
12. [Cannabis and cannabinoids as drugs].
Khiabani HZ; Mørland J
Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
[TBL] [Abstract][Full Text] [Related]
13. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
McKallip RJ; Lombard C; Fisher M; Martin BR; Ryu S; Grant S; Nagarkatti PS; Nagarkatti M
Blood; 2002 Jul; 100(2):627-34. PubMed ID: 12091357
[TBL] [Abstract][Full Text] [Related]
14. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.
Burstein SH
Curr Pharm Des; 2000 Sep; 6(13):1339-45. PubMed ID: 10903396
[TBL] [Abstract][Full Text] [Related]
15. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.
Zurier RB; Sun YP; George KL; Stebulis JA; Rossetti RG; Skulas A; Judge E; Serhan CN
FASEB J; 2009 May; 23(5):1503-9. PubMed ID: 19124557
[TBL] [Abstract][Full Text] [Related]
16. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
Johnson DR; Stebulis JA; Rossetti RG; Burstein SH; Zurier RB
J Cell Biochem; 2007 Jan; 100(1):184-90. PubMed ID: 16927387
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid.
Zurier RB; Rossetti RG; Burstein SH; Bidinger B
Biochem Pharmacol; 2003 Feb; 65(4):649-55. PubMed ID: 12566094
[TBL] [Abstract][Full Text] [Related]
18. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.
Sánchez C; Galve-Roperh I; Canova C; Brachet P; Guzmán M
FEBS Lett; 1998 Sep; 436(1):6-10. PubMed ID: 9771884
[TBL] [Abstract][Full Text] [Related]
19. PPAR-gamma: a nuclear receptor with affinity for cannabinoids.
Burstein S
Life Sci; 2005 Aug; 77(14):1674-84. PubMed ID: 16005906
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.
Blázquez C; Salazar M; Carracedo A; Lorente M; Egia A; González-Feria L; Haro A; Velasco G; Guzmán M
Cancer Res; 2008 Mar; 68(6):1945-52. PubMed ID: 18339876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
